phm

From a disappointing 1.2, the ratings of TikTok have moved up to 4.4 after Google removed over 8 million negative reviews from the Play Store. Looks like TikTok has resumed its throne on  Google Play Store . From a disappointing 1.2, the ratings of TikTok have moved up to 4.4 after Google removed over 8 million negative reviews from the  Play Store . TikTok's ratings fell drastically after a post glorifying acid attack on woman went viral on the app. Not just the ratings on Play Store, Hashtags pressing TikTok to be banned and India against TikTok also started trending on Twitter. As per comment posting guidelines, Google can remove negative comments and ratings. A Google spokesperson told the  Gadgets 360  without specifically mentioning TikTok that actions are taken against inappropriate ratings when it is a case of spam abuse. "Play Store ratings enable users to provide helpful feedback about their experience with apps and content, for the benefit of others to mak...

Social media giant Facebook had announced a newgroup-calling app called the CatchUp. The CatchUp would allow users to set up group calls with up to 8 people. Social media giant Facebook had announced a new group-calling app called the CatchUp. The CatchUp would allow users to set up group calls with up to 8 people. However, there is a catch, it is not a video calling app but an audio-only app. The app is being developed by Facebook NPE. For video-calling services, Facebook had earlier released a  Messenger Rooms  app that can allow up to 50 people to connect in a single call. However, this is Facebook's first audio-only application. Talking about the CatchUp app Facebook had said in a blog post, "Keeping in touch with friends and family is important, especially during this time of physical distancing. Messaging and video calls are great ways to send a quick update or connect with someone face-to-face, but speaking to someone over the phone offers a unique balance of both conve...

Coronavirus vaccine update: Even though these candidate vaccines have produced encouraging results in early stages, a clearer picture can only emerge when a diverse population gets tested COVID-19 vaccine: Even as multiple vaccine candidates have entered various levels of trials, experts believe that a coronavirus vaccine might not be found before next year. So far, globally, ten vaccine candidates are getting tested on healthy volunteers, while 114 are in preliminary stages of development. Even the Indian pharma firms are actively contributing to the cause. Union Health Minister  Harsh Vardhan  recently said that there are 14 candidate COVID-19 vaccines for the virus in India which are at different levels of development. China's CanSino adenovirus vaccine,  Oxford University 's adenovirus vaccine, Moderna's mRNA vaccine, Novavax's vaccine are among the most promising candidates globally so far. Also read:  Coronavirus update: Moderna's COVID-19 vaccine shows positi...

American pharmaceutical giant Pfizer is conducting clinical trials with German firm BioNTech on several probable vaccines in Europe and the United States American drugmaker  Pfizer  has claimed that a  COVID-19 vaccine could be ready by October-end this year. The pharmaceutical company is conducting clinical trials with German firm BioNTech on several probable vaccines in Europe and the United States. "If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can...have a vaccine around the end of October," Pfizer CEO  Albert Bourla was reported by the Times of Israel as saying. The report also cited UK drug firm AstraZeneca's head  Pascal Soriot  who said that one or more coronavirus vaccines could start rolling out by the end of this year (2020). AstraZeneca is working in partnership with the  University of Oxford  to develop and distribute a vaccine being piloted in Britain. Also Read:  Co...

Doubts over Moderna vaccine emerge after volunteer says he started getting chills within hours of getting home from his second dose. Track latest coronavirus vaccine updates Less than six months after the world first learnt about the novel  coronavirus  (SARS-CoV 2) in Wuhan, China, there currently are more than 110 teams in contention, speeding up efforts to produce a ready vaccine. A lot of vaccines are in the development phase in India as well, and medicinal trials are also going on for treatment. The reason behind the rush is a staggering number of Covid-19 cases (past 6 million) and death toll (more than 350,000 globally). In India alone, there are 151,876 corona cases as of May 27. Large pharmaceutical companies such as Gilead Sciences, Pfizer, Moderna, among others, are racing to find a successful vaccine. In India, Ramdev's Patanjali has also joined the race to develop  coronavirus  vaccine. How soon can the world expect a Covid-19 vaccine? A vaccine would no...

Coronavirus (Covid-19) vaccine latest update: Shares of Moderna Inc tumble over doubts over vaccine; Novavax Inc buys vaccine manufacturing plant from Serum Institute of India Coronavirus  ( Covid-19 ) vaccine latest update:  As countries scramble  to stem the spread of Covid-19 , the US government’s top infectious disease expert, Anthony Fauci, has provided some hope of a vaccine being ready as early as November even as epidemiology experts have warned that the novel coronavirus might not go away with the development of an injection. The experts have said the novel coronavirus would likely remain for years to come, and may eventually, become endemic like HIV, measles and chickenpox, a report in The Washington Post said. Meanwhile, US biotechnology company Novavax, which started human trials of its NVX-CoV2373 vaccine for Covid-19 earlier this week in Australia, is buying a manufacturing plant from Serum Institute of India in its bid to produce one billion doses next year...

Drug Target Review ’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines. Novel broad-spectrum antibiotic compound effective against coronaviruses Researchers have identified new compounds with activity against the novel coronavirus called COVID-19 and other coronaviruses eg, severe acute respiratory syndrome virus (SARS-CoV) and Middle-East respiratory disease virus ( MERS-CoV ). cientists working towards a broad-spectrum antiviral able to combat all the coronaviruses identified a target – a ‘main protease’ that is essential for viral replication. According to the team, enteroviruses, such as those causing foot and mouth disease and the common cold, also have a similar protein called the 3C protease for viral replication, so can also be treated through this target. Using X-ray crystallography to examine the structure of the proteases, the researchers designed a series of α-ketoamide compounds that would bind...